fr   en

Browse by date
Or search by keyword
Date: 2010-06-07
Company: Cytheris (France)
Investors: CDC Entreprises (France), acting for the Strategic Investment Fund (FSI) Bioam Gestion (France) Caisse de dépôt et Placement du Québec (Canada) CDC Innovation (France) Crédit Agricole Private Equity (France) Forbion Capital Partners (The Netherlands).
Amount: € 12 million
Planned use: Proceeds will further advance studies of Interleukin-7 in HIV, HBV, HCV and Oncology;
Currently, Cytheris is conducting multiple international investigations of IL-7 in HIV, HBV, HCV, idiopathic CD4 lymphocytopenia (sponsored by NIAID/NIH) and cancer, the latter including an NCI/NIH-sponsored study of IL-7 in combination with dendritic cell vaccines in a pilot study of tumor vaccination in children, and a study designed to restore CD4+ and CD8+ counts following T-cell depletion due to bone marrow or peripheral blood stem cell transplant (being conducted at the Memorial Sloan-Kettering Cancer Center in New York City).
(See clinical_studies).

Other: Cytheris has completed a € 12 million Series D financing. New investor, CDC Entreprises (France), acting for the Strategic Investment Fund (FSI), participated in the round along with existing investors. In conjunction with the CDC Entreprises investment, Marie-Laure Garrigues, Director of Investments at CDC Entreprises, will join the Cytheris board of directors as an observer.